Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Patching Gaps In Global Pneumococcal Vaccination
Since 2000, U.S. infants have been routinely immunized against pneumococcal (Streptococcus pneumoniae) infection, but the existing vaccine"s expense puts it out of reach for most developing countries, where almost one million children die from pneumococcal infections each year. Richard Malley, MD, of the Division of Infectious Diseases at Children"s Hospital Boston, is at work on a pneumococcal vaccine that meets developing countries" needs it can be made cheaply, withstands high temperatures without refrigeration, and can be given without needles, avoiding the need for sterile procedures and medical professionals to administer it. Also, because it is a whole-cell vaccine, it should provide protection against virtually all of the 91 pneumococcal serotypes that infect people worldwide. (The U.S. vaccine covers only seven.)

Local Groups React To Proposed Changes In Medicare And Medicaid
Local news coverage details concerns about Medicare and Medicaid spending reductions that could affect senior and nursing care.
News of the day
Preclinical Proof-of-Concept Studies Published For Novavax Seasonal Influenza Virus-Like-Particle Vaccine
Novavax, Inc. (Nasdaq: NVAX) announced publication of the preclinical study results that supported the clinical development of the company"s investigational VLP vaccine against the H3N2, H1N1 and B influenza strains. The study, which was conducted by scientists from the University of Pittsburgh, Center for Vaccine Research and Novavax, was published in the June 24, 2009 online issue of PLoS ONE. The vaccine contains three VLPs mixed together in a single formulation; each made up of the hemagglutinin (HA), neuraminidase (NA) and matrix 1 (M1) proteins from the representative strains. These proteins are important for broad protection against influenza, which is responsible for nearly 200,000 hospitalizations and 36,000 deaths in the U.S. each year. The vaccine is currently in Phase 2 clinical testing.
Mental Health

Announcing National MS And Parkinson's Disease Registries Act

Senator Byron Dorgan (ND) on Tuesday introduced legislation that would for the first time establish a national coordinated system to collect and analyze data on multiple sclerosis and Parkinson"s disease. Accurate incidence and prevalence information on these two diseases currently does not exist. Click here to ask your Senator to support this legislation. The National MS and Parkinson"s Disease Registries Act would establish separate registries for MS and Parkinson"s disease at the Agency for Toxic Substances and Disease Registry at the Centers for Disease Control and Prevention (CDC). The National Multiple Sclerosis Society has worked closely with the Parkinson"s Action Network to introduce legislation in both chambers of Congress to address the lack of accurate incidence information that both communities face. Both organizations will be advocating to advance this legislation and have it signed into law in the 111th Congress. "I often receive letters from people living with MS who are concerned about whether the current numbers accurately reflect the MS community," National MS Society President and CEO Joyce Nelson said. "A national multiple sclerosis registry will give us a clearer picture of the impact of MS and help us better serve all those who live with this disease." Lack of core information and knowledge about who has MS and Parkinson"s disease inhibits progress in biomedical research, the development of new and better treatments, and the creation of programs and services to help people live independent and productive lives while fighting these diseases. These registries will authorize the CDC to develop national coordinated systems to collect and analyze existing MS and Parkinson"s disease data. The epidemiological data collected and analyzed through the registries will provide a foundation for better evaluating and understanding issues such as geographic clusters of diagnosis, genetic and environmental risk factors, variances in gender ratio, disease burden, and changes in health care practices. This important legislation also sets the ground work for developing epidemiological registries for other neurological diseases and disorders. National MS Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009